Stephane Le Vu
Overview
Explore the profile of Stephane Le Vu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
551
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Semenzato L, Le Vu S, Zureik M
JAMA
. 2025 Jan;
333(8):721-722.
PMID: 39869358
No abstract available.
2.
Le Vu S, Bertrand M, Semenzato L, Jabagi M, Botton J, Drouin J, et al.
Nat Commun
. 2024 Sep;
15(1):7745.
PMID: 39232036
Myocarditis is the most salient serious adverse event following messenger RNA-based Covid-19 vaccines. The highest risk is observed after the second dose compared to the first, whereas the level of...
3.
Botton J, Bertrand M, Jabagi M, Duranteau L, Bouillon K, Drouin J, et al.
Vaccine
. 2024 Sep;
42(24):126252.
PMID: 39226788
Background: COVID-19 vaccination has been inconsistently associated with an increased risk of heavy menstrual bleeding in previous studies. This study aimed to assess the risk of heavy menstrual bleeding requiring...
4.
Semenzato L, Le Vu S, Botton J, Bertrand M, Jabagi M, Drouin J, et al.
JAMA
. 2024 Aug;
PMID: 39186694
Importance: Although patients with myocarditis after COVID-19 mRNA vaccination appear to have a good prognosis near hospital discharge, their longer-term prognosis and management remain unknown. Objective: To study the cardiovascular...
5.
Turpin A, Semenzato L, Le Vu S, Jabagi M, Bouillon K, Drouin J, et al.
J Infect Public Health
. 2024 Jun;
17(7):102450.
PMID: 38823086
Background: In spite of major effectiveness, a residual risk after COVID-19 primary vaccination was identified, in particular, for vulnerable individuals of advanced age or with comorbidities. Less is known about...
6.
Bougeard S, Huneau-Salaun A, Attia M, Richard J, Demeret C, Platon J, et al.
JMIR Public Health Surveill
. 2023 Nov;
9:e46898.
PMID: 38015594
Background: The seroprevalence of SARS-CoV-2 infection in the French population was estimated with a representative, repeated cross-sectional survey based on residual sera from routine blood testing. These data contained no...
7.
Semenzato L, Botton J, Le Vu S, Jabagi M, Cuenot F, Drouin J, et al.
Open Forum Infect Dis
. 2023 Oct;
10(10):ofad460.
PMID: 37808897
Background: Knowing the duration of effectiveness of coronavirus disease 2019 (COVID-19) booster doses is essential to providing decision-makers with scientific arguments about the frequency of subsequent injections. We estimated the...
8.
Le Vu S, Bertrand M, Botton J, Jabagi M, Drouin J, Semenzato L, et al.
Neurology
. 2023 Oct;
101(21):e2094-e2102.
PMID: 37788935
Background And Objectives: Guillain-Barré syndrome (GBS) has been inconsistently associated with some coronavirus disease 2019 (COVID-19) vaccines. We aimed to quantify the risk of GBS according to the type of...
9.
Jabagi M, Bertrand M, Botton J, Le Vu S, Weill A, Dray-Spira R, et al.
N Engl J Med
. 2023 Mar;
388(15):1431-1432.
PMID: 36988584
No abstract available.
10.
Bouillon K, Baricault B, Botton J, Jabagi M, Bertrand M, Semenzato L, et al.
BMJ Med
. 2023 Mar;
1(1):e000104.
PMID: 36936561
Objective: To estimate the effectiveness of the three covid-19 vaccines by Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and Oxford-AstraZeneca (ChAdOx1-S) in people after receiving two doses. Design: Cohort study. Setting: Nationwide, population...